{"organizations": [], "uuid": "3a14eb21ba2203fa6e4cd68e4efd19b96a07aa97", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180501.html", "section_title": "Archive News &amp; Video for Tuesday, 01 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oxford-immunotec-reports-q1-loss-p/brief-oxford-immunotec-reports-q1-loss-per-share-0-40-idUSASC09YJ5", "country": "US", "domain_rank": 408, "title": "BRIEF-Oxford Immunotec Reports Q1 Loss Per Share $0.40", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T19:17:00.000+03:00", "replies_count": 0, "uuid": "3a14eb21ba2203fa6e4cd68e4efd19b96a07aa97"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oxford-immunotec-reports-q1-loss-p/brief-oxford-immunotec-reports-q1-loss-per-share-0-40-idUSASC09YJ5", "ord_in_thread": 0, "title": "BRIEF-Oxford Immunotec Reports Q1 Loss Per Share $0.40", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oxford immunotec global plc", "sentiment": "negative"}, {"name": "united states", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "oxford immunotec", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1 (Reuters) - Oxford Immunotec Global PLC:\n* OXFORD IMMUNOTEC REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 REVENUE $21.4 MILLION VERSUS I/B/E/S VIEW $21 MILLION * Q1 EARNINGS PER SHARE VIEW $-0.45 — THOMSON REUTERS I/B/E/S\n* OXFORD IMMUNOTEC - UNITED STATES REVENUE WAS $13.4 MILLION IN THE QUARTER , A 1% DECREASE FROM THE PRIOR YEAR PERIOD\n* QTRLY GROSS MARGIN WAS 50.4%, A DECREASE OF 80 BASIS POINTS FROM GROSS MARGIN OF 51.2% IN Q1 2017\n* OXFORD IMMUNOTEC - FOR 2018, CO NOW EXPECTS REVENUE OF $112 MILLION -$115 MILLION, REPRESENTING 9% - 12% YEAR-OVER-YEAR GROWTH AS REPORTED\n* FY2018 REVENUE VIEW $112.3 MILLION — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-01T19:17:00.000+03:00", "crawled": "2018-05-02T16:06:31.010+03:00", "highlightTitle": ""}